Arkolith/Insider Trading/STSA/Form 4

Riebe Michael T

DirectorSatsuma Pharmaceuticals, Inc. (STSA) · full profile →Form 4 · filed Jun 8, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
6
0 non-derivative · 6 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 8, 2023Disposed to issuer(D)10K—$00
Jun 8, 2023Disposed to issuer(D)20K—$00
Jun 8, 2023Disposed to issuer(D)13K——0
Jun 8, 2023Disposed to issuer(D)15K—$00
Jun 8, 2023Disposed to issuer(D)30K—$00
Jun 8, 2023Disposed to issuer(D)13K—$00

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000899243-23-014894) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML